<DOC>
	<DOCNO>NCT01432223</DOCNO>
	<brief_summary>The purpose study evaluate efficacy term pathological complete response ( pCR ) rate efficacy preoperative administration Anthracycline-based regimen follow Nab-paclitaxel Trastuzumab patient HER2 positive operable breast cancer .</brief_summary>
	<brief_title>Primary Chemotherapy With Anthracycline Followed Nab-paclitaxel Trastuzumab</brief_title>
	<detailed_description>Four cycle anthracycline-based regimen follow four cycle Nab-paclitaxel Trastuzumab administrate . Anthracycline-based regimen ( d1 , q3w ) : EC ( Epirubicin 90mg/m2 Cyclophosphamide 600mg/m2 ) AC ( Doxorubicin 60mg/m2 Cyclophosphamide 600mg/m2 ) FEC ( Fluorouracil 500mg/m2 , Epirubicin 100mg/m2 Cyclophosphamide 500mg/m2 ) Nab-paclitaxel 260mg/m2 ( d1 , q3w ) Trastuzumab ( d1 , q3w ) give dose 8 mg/kg IV day 1 first treatment cycle 90 min , subsequently give dose 6 mg/kg 30 min .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm invasive breast cancer T1c3 N02a Confirmed hormonal receptor status HER2 positive confirm IHC 3+ FISH+ LVEF &gt; 50 % echocardiogram MUGA Adequate EKG No prior treatment breast cancer PS 01 Required baseline laboratory data WBC &gt; 4,000/mm3 Neut &gt; 2,000/mm3 PLT &gt; 100,000/mm3 Hb &gt; 9.0g/dl AST ALT &lt; ULNx2.5 TBil &lt; 1.5mg/dl Serum creatinin &lt; 1.5mg/dl Written inform consent With history hypersensitivity reaction important drug study With history invasive breast cancer Bilateral invasive breast cancer Patients medical condition render intolerant primary chemotherapy relate treatment , include infection , diarrhea , intestinal paralysis , severe Diabetes Mellitus Positive HBs antigen history HVB With history congestive heart failure , uncontrolled symptomatic angina pectoris , arrhythmia myocardial infarction , poorly control hypertension With severe edema With severe peripheral neuropathy With severe psychiatric disorder Pregnant nursing woman Cases physician judge improper entry trial</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Trastuzumab</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>Primary chemotherapy</keyword>
</DOC>